<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_a_032.html</title>
</head>
<body>
<p>* The company&#x27;s strategic positioning shifted from aspirational to actively redefining its market.</p>
<p>* A competitive claim of being the &quot;only&quot; allograft product was removed.</p>
<p>* A new product, AxoTouch Two Point Discriminator, was introduced.</p>
<p>* The main driver of revenue growth is now increased usage from existing accounts.</p>
<p>* A new &quot;Recent Developments&quot; section was added to the disclosure.</p>
<p>* The company refinanced its debt, terminating its prior agreement with PDL BioPharma.</p>
<p>* A new $25 million term loan and revenue interest agreement was established.</p>
<p>* New registered offerings of common stock were conducted to raise capital.</p>
<p>* Intellectual property is now included as collateral for the company&#x27;s debt.</p>
<p>* The previous disclosure on goodwill impairment and its write-off was removed.</p>
<p>* The accounting policy for the debt&#x27;s effective interest rate was completely revised.</p>
<p>* A new sales strategy focusing on account &quot;breadth, depth and quality&quot; was disclosed.</p>
<p>* The company extinguished its prior long-term royalty contract debt facility.</p>
<p>* A new term loan agreement was established with a new lender.</p>
<p>* A new, separate revenue interest agreement was also executed.</p>
<p>* The new loan agreement includes an option for future additional borrowing.</p>
<p>* Research focus shifted from a clinical trial to a Biologics License Application.</p>
<p>* A favorable product mix is newly cited as a driver of gross profit.</p>
<p>* The sales force is now described as gaining penetration and driving leverage.</p>
<p>* Product pipeline development is a newly disclosed area of R&amp;D spending.</p>
<p>* The PDL royalty contract was fully repaid and all obligations were terminated.</p>
<p>* A new term loan and revenue interest agreement was established with Three Peaks.</p>
<p>* An equity sale was completed with the new lender, Three Peaks.</p>
<p>* An additional equity sale was completed with the former lender, PDL.</p>
<p>* A new public offering of common stock was completed post year-end.</p>
<p>* The specific risk disclosure regarding PDL minimum royalty payments was removed.</p>
<p>* Working capital and the current ratio significantly decreased.</p>
<p>* Cash flow from financing activities changed from a large source to a use of cash.</p>
<p>* Investment spending increased for headquarters and new distribution facility expansion.</p>
<p>* A new disclosure was added for an upcoming revenue recognition accounting standard.</p>
</body>
</html>
